Jeffrey Sosman

Jeffrey Sosman

UNVERIFIED PROFILE

Are you Jeffrey Sosman?   Register this Author

Register author
Jeffrey Sosman

Jeffrey Sosman

Publications by authors named "Jeffrey Sosman"

Are you Jeffrey Sosman?   Register this Author

100Publications

10306Reads

36Profile Views

Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors.

Cancer 2020 Jan 3;126(2):322-328. Epub 2019 Oct 3.

Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32542DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952563PMC
January 2020

Targeted Therapy and Immunotherapy: Emerging Biomarkers in Metastatic Melanoma.

Pigment Cell Melanoma Res 2019 Nov 9. Epub 2019 Nov 9.

Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical Center, Chicago, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12847DOI Listing
November 2019

A Time to Ignore "No Meat, No Treat".

Int J Radiat Oncol Biol Phys 2019 10;105(2):245-246

Department of Radiation Oncology, Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2019.05.026DOI Listing
October 2019

Past, Current, and Future of Immunotherapies for Prostate Cancer.

Front Oncol 2019 11;9:884. Epub 2019 Sep 11.

Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00884DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749031PMC
September 2019

Adverse Events Associated With Immune Checkpoint Inhibitors-Reply.

JAMA 2019 03;321(12):1219-1220

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2018.22123DOI Listing
March 2019

Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis.

J Natl Compr Canc Netw 2019 Feb;17(2):114-117

bDepartment of Medicine, University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7070DOI Listing
February 2019

CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy.

Nat Commun 2019 01 11;10(1):150. Epub 2019 Jan 11.

Department of Medicine-Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41467-018-08123-8
Publisher Site
http://dx.doi.org/10.1038/s41467-018-08123-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329764PMC
January 2019

BRAF and MEK inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors.

Pigment Cell Melanoma Res 2018 11 28;31(6):708-719. Epub 2018 Jun 28.

Department of Cell and Developmental Biology, School of Medicine, Vanderbilt University, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12712DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188784PMC
November 2018

Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.

Am J Clin Dermatol 2018 Oct;19(5):657-670

Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-018-0359-4DOI Listing
October 2018

Immune Checkpoint Inhibitor Toxicity in 2018.

JAMA 2018 10;320(16):1702-1703

Department of Medicine, Northwestern University Medical Center, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.20
Publisher Site
http://dx.doi.org/10.1001/jama.2018.13995DOI Listing
October 2018

Melanoma: What do all the mutations mean?

Cancer 2018 09 17;124(17):3490-3499. Epub 2018 Apr 17.

Department of Medicine, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31345
Publisher Site
http://dx.doi.org/10.1002/cncr.31345DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191351PMC
September 2018

Reporting of immune checkpoint inhibitor-associated myocarditis - Authors' reply.

Lancet 2018 08;392(10145):384-385

Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)31556-3DOI Listing
August 2018

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.

Lancet 2018 03;391(10124):933

Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)30533-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668330PMC
March 2018

Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction.

J Immunother Cancer 2016 18;4:60. Epub 2016 Oct 18.

Departments of Medicine, Vanderbilt Ingram Cancer Center, 777 PRB, 2220 Pierce Ave., Nashville, TN 37232 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0166-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067899PMC
February 2018

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

J Clin Oncol 2018 02 3;36(4):383-390. Epub 2017 Jul 3.

James Larkin, Royal Marsden NHS Foundation Trust, London; Paul Lorigan, The Christie National Health Service Foundation Trust, Manchester, United Kingdom; David Minor, California Pacific Medical Center Research Institute; Adil Daud, University of California San Francisco, San Francisco; Bartosz Chmielowski, University of California, Santa Monica, CA; Sandra D'Angelo, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; Jeffrey Weber, Perlmutter Cancer Center at New York University-Langone Medical Center, New York; Nikhil Khushalani, Roswell Park Cancer Institute, Buffalo, NY; Gerald Linette, Washington University, St. Louis, MO; Christopher D. Lao, University of Michigan, Ann Arbor, MI; Kenneth Grossmann, Huntsman Cancer Institute, Salt Lake City, UT; Mario Sznol, Yale Comprehensive Cancer Center, New Haven, CT; Jeffrey Sosman, Northwestern University, Chicago, IL; Dana Walker, George Kong, and Christine Horak, Bristol-Myers Squibb, Princeton, NJ; Bart Neyns, University Hospital, Vrije Universiteit Brussel, Brussels, Belgium; Michael Smylie, Cross Cancer Institute, Edmonton, Alberta; Wilson H. Miller Jr, Jewish General Hospital and Segal Cancer Centre, McGill University, Montreal, Quebc, Canada; Ralf Gutzmer, Medizinische Hochschule Hannover, Hannover; Jessica C. Hassel, Nationale Centrum für Tumorerkrankungen Heidelberg, Heidelberg; Dirk Schadendorf, University Hospital Essen, Essen, Germany; and Christoph Hoeller, Medical University of Vienna, Wien, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.8023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804912PMC
February 2018

Distinct Patterns of Acral Melanoma Based on Site and Relative Sun Exposure.

J Invest Dermatol 2018 02 1;138(2):384-393. Epub 2017 Sep 1.

Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA; Robert H. Lurie Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2017.08.022DOI Listing
February 2018

A Critical Need for Better Cancer Immunotherapy Models: Are Organotypic Tumor Spheroid Cultures the Answer?

Cancer Discov 2018 02;8(2):143-145

Department of Medicine, Northwestern University, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-17-1356DOI Listing
February 2018

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2017 10 11;377(14):1345-1356. Epub 2017 Sep 11.

From the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W., M.A.P., M.K.C.); Oncology Institute of Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua (V.C.-S.), European Institute of Oncology, Milan (P.F.F.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; University of Colorado, Denver (R.G.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); Aix-Marseille University, Hôpital de la Timone, Marseille (J.-J.G.), and Assistance Publique-Hôpitaux de Paris, Dermatology and Centres d'Investigation Clinique, INSERM Unité 976, Hôpital Saint-Louis, Université Paris Diderot, Paris (C.L.) - both in France; Texas Oncology-Baylor Cancer Center, Dallas (C.L.C.); University of Michigan, Ann Arbor (C.D.L.); the College of Medicine, Swansea University, Swansea (J.W.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Cross Cancer Institute, Edmonton, AB (M.S.), and Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Universitäts Spital, Zurich, Switzerland (R.D.); Tasman Oncology Research, Southport Gold Coast, QLD (A.H.), Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney (M.S.C.), and Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and Peter MacCallum Cancer Centre (G.M.) and the Olivia Newton-John Cancer Research Institute, University of Melbourne (J.C.), Melbourne, VIC - all in Australia; Netherlands Cancer Institute, Amsterdam (J.H.); University Hospitals Leuven, KU Leuven, Leuven, Belgium (O.B.); General University Hospital Gregorio Marañón, Madrid (I.M.-R.); Northwestern University, Chicago (J.S.); Bristol-Myers Squibb, Princeton, NJ (D.W., L.R., R.B.); and the Dana-Farber Cancer Institute, Boston (F.S.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709684DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706778PMC
October 2017

Novel Targeted Therapies for Metastatic Melanoma.

Cancer J 2017 Jan/Feb;23(1):54-58

From the Division of Hematology/Oncology, Northwestern Feinberg School of Medicine, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000242DOI Listing
August 2017

Cancer Immunotherapies: Are They as Effective in the Elderly?

Drugs Aging 2017 08;34(8):567-581

Department of Medicine-Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 300 E Superior Street-Tarry 4-726, Chicago, IL, 60611, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40266-017-0479-1
Publisher Site
http://dx.doi.org/10.1007/s40266-017-0479-1DOI Listing
August 2017

Emerging growth factor receptor antagonists for the treatment of advanced melanoma.

Expert Opin Emerg Drugs 2017 06;22(2):165-174

b Division of Hematology Oncology , Chicago , IL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2017.1336537DOI Listing
June 2017

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

J Clin Oncol 2017 Mar 30;35(8):885-892. Epub 2017 Jan 30.

Sanjiv S. Agarwala, Saint Luke's University Hospital, Easton; Uma N. Rao, Ahmad A. Tarhini, Terry L. Evans, and John M. Kirkwood, University of Pittsburgh Medical Center, Pittsburgh, PA; Sandra J. Lee, and Waiki Yip, Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA; Gary I. Cohen, Greater Baltimore Medical Center, Baltimore, MD; Douglas S. Reintgen, Lakeland Regional Cancer Center, Lakeland; Vernon K. Sondak, H. Lee Moffitt Cancer Center, Tampa, FL; Joanna M. Brell, MetroHealth Medical Center, Cleveland; William E. Carson, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Mark R. Albertini, University of Wisconsin Hospital, Madison, WI; Michael B. Atkins, Georgetown Medical Center, Washington, DC; Shaker R. Dakhil, Cancer Center of Kansas, Wichita, KS; Robert M. Conry, University of Alabama at Birmingham, Birmingham, AL; Jeffrey A. Sosman, Vanderbilt University, Nashville; Alberto S. Pappo, Saint Jude Children's Research Hospital Oncology, Memphis, TN; Lawrence E. Flaherty, Wayne State University/Karmanos Cancer Institute, Detroit, MI; Michael G. Smylie, Cross Cancer Institute, Edmonton, Canada; and Richard F. Kefford, Sydney West Area Health Service, Westmead, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.2951DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455684PMC
March 2017

PD-1/PD-L1 blockade in renal cell cancer.

Expert Rev Clin Immunol 2017 Jan 28;13(1):77-84. Epub 2016 Jul 28.

b Department of Medicine , Northwestern University Medical Center , Chicago , IL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2016.1214575DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555220PMC
January 2017

Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.

J Immunother 2017 01;40(1):31-35

*Vanderbilt University Medical Center, Nashville, TN †Beth Israel Deaconess Medical Center ‡Dana-Farber Cancer Institute §Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/immunotherapy-journal/2017/0100
Web Search
http://dx.doi.org/10.1097/CJI.0000000000000148DOI Listing
January 2017

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

J Clin Oncol 2017 Jan 7;35(2):226-235. Epub 2016 Nov 7.

Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.67.9258
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.67.9258DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559888PMC
January 2017

Myocarditis with Immune Checkpoint Blockade.

N Engl J Med 2017 01;376(3):292

Vanderbilt School of Medicine, Nashville, TN

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1615251DOI Listing
January 2017

Fulminant Myocarditis with Combination Immune Checkpoint Blockade.

N Engl J Med 2016 Nov;375(18):1749-1755

From the Departments of Medicine (D.B.J., J.M.B., M.H., I.P., M.R.A., T.L.B., J.R.B., D.A.S., E.J.P., M.A.P., D.M.R., J.A.S., J.J.M.), Cancer Biology (J.M.B., J.J.M.), Pathology, Microbiology, and Immunology (M.L.C., L.C.-O., R.D.H.), Biostatistics (Y.X.), Pharmacology (D.M.R.), and Biomedical Informatics (Y.X., D.M.R.), the Cardio-oncology Program (D.A.S., J.J.M.), the Breast Cancer Research Program (J.M.B.), and the Center for Quantitative Sciences (Y.X.), Vanderbilt University Medical Center, Nashville; the Department of Medicine (S.C.) and the Division of Neuroimmunology (S.C., I.J.K.), Beth Israel Deaconess Medical Center, the Departments of Medicine (B.A.O., C.E.S., J.G.S.) and Pathology (A.H.L.), Brigham and Women's Hospital, the Department of Genetics, Harvard Medical School (J.G., C.E.S., J.G.S.) - all in Boston; Howard Hughes Medical Institute, Chevy Chase, MD (C.E.S.); Bristol-Myers Squibb, New York (N.K., G.P., D.S.R., J.S.D.); Neon Therapeutics, Cambridge, MA (R.P.D.); and the Departments of Pathology (J.M.T., R.A.A.), Dermatology (J.M.T.), and Oncology (L.A.D.), Johns Hopkins University, Baltimore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609214DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5247797PMC
November 2016

Responses to immune checkpoint inhibitors in nonagenarians.

Oncoimmunology 2016 18;5(11):e1234572. Epub 2016 Oct 18.

Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center , Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2016.1234572DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139628PMC
October 2016

Advancements in unresectable melanoma: a multidisciplinary perspective.

Melanoma Manag 2016 Sep 16;3(3):171-175. Epub 2016 Aug 16.

Division of Medical Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt-2016-0003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094606PMC
September 2016

CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment.

J Am Med Inform Assoc 2016 07 23;23(4):692-700. Epub 2016 Mar 23.

Department of Medicine, Division of Hematology/Oncology, Vanderbilt University, Nashville, TN, USA. Department of Biomedical Informatics, Vanderbilt University, Nashville, TN, USA. Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jamia/ocw008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926743PMC
July 2016

Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab.

Cancer Immunol Res 2016 07 13;4(7):569-73. Epub 2016 May 13.

Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0281DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940026PMC
July 2016

Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.

J Natl Cancer Inst 2016 Jun 30;108(6):djv406. Epub 2015 Dec 30.

Tennessee Valley Healthcare System, Department of Veterans Affairs, Nashville, TN (AEV, CAJ, JY, JSP, DR, AR); Department of Cancer Biology (AEV, AJ, JY, SCC, JSP, DR, AR), Center for Quantitative Sciences (SCC), Division of Cancer Biostatistics, Department of Biostatistics (GDA, YS), Division of Hematology/Oncology, Department of Medicine (JAS), Vanderbilt University Medical Center, Nashville, TN; HudsonAlpha Institute for Biotechnology, Huntsville, Alabama (NP, SEL); Division of Surgical Oncology, Department of Surgery, Vanderbilt University School of Medicine, Nashville, TN (MK); Translational Medicine, Takeda Pharmaceuticals International Co, Cambridge, MA (JAE).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv406DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849355PMC
June 2016

Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy.

Cancer Immunol Res 2016 06 10;4(6):474-480. Epub 2016 Mar 10.

Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0213DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891280PMC
June 2016

Emerging targeted therapies for melanoma.

Expert Opin Emerg Drugs 2016 Jun 17;21(2):195-207. Epub 2016 May 17.

a Department of Medicine , Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center , Nashville , TN , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2016.1184644DOI Listing
June 2016

Melanoma driver mutations and immune therapy.

Oncoimmunology 2016 May 10;5(5):e1051299. Epub 2016 Mar 10.

Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center , Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2015.1051299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910708PMC
May 2016

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.

J Clin Oncol 2016 Mar 11;34(8):833-42. Epub 2016 Jan 11.

David F. McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Jeffrey A. Sosman, Vanderbilt University School of Medicine; Jeffrey R. Infante, Sarah Cannon Research Institute, Nashville, TN; Mario Sznol, Yale Cancer Center, New Haven, CT; Christophe Massard, Gustave Roussy, Villejuif Cedex, France; Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Omid Hamid, Angeles Clinic and Research Institute, Santa Monica; Marcella Fassò, Yan V. Wang, Wei Zou, Priti S. Hedge, and Gregg D. Fine, Genentech, South San Francisco, CA; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; and Thomas Powles, Barts Cancer Institute Centre for Experimental Cancer Medicine and the Royal Free National Health Service Trust, Queen Mary University of London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.7421DOI Listing
March 2016

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

J Clin Oncol 2016 Mar 25;34(8):871-8. Epub 2016 Jan 25.

Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.62.9345
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.9345DOI Listing
March 2016

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Cell 2016 Mar 17;165(1):35-44. Epub 2016 Mar 17.

Division of Dermatology, Department of Medicine, University of California, Los Angeles, CA 90095-1662, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095-1662, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095-1662, USA; David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1662, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2016.02.065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808437PMC
March 2016

A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma.

Pigment Cell Melanoma Res 2016 Jan 20;29(1):101-3. Epub 2015 Aug 20.

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12394DOI Listing
January 2016

Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma.

Curr Oncol Rep 2016 Jan;18(1)

Department of Medicine, Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 777 Preston Research Building, 2220 Pierce Avenue, Nashville, TN, 37232, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s11912-015-0485
Web Search
http://link.springer.com/10.1007/s11912-015-0485-6
Publisher Site
http://dx.doi.org/10.1007/s11912-015-0485-6DOI Listing
January 2016

Combination Immunotherapy: An Emerging Paradigm in Cancer Therapeutics.

Oncology (Williston Park) 2015 12;29(12):1005-6

View Article

Download full-text PDF

Source
December 2015

Melanoma and a Headache. Diagnosis: Hypophysitis.

JAMA Oncol 2015 Nov;1(8):1167-8

Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.2537DOI Listing
November 2015

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.

Cancer 2015 Nov 11;121(22):4007-15. Epub 2015 Aug 11.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29622DOI Listing
November 2015

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

N Engl J Med 2015 Nov 25;373(19):1803-13. Epub 2015 Sep 25.

From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York; Institut Gustave Roussy, Villejuif (B.E.), and Bordeaux University Hospital, Hôpital Saint André, Bordeaux (A.R.) - both in France; Beth Israel Deaconess Medical Center (D.F.M.) and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.) - all in Boston; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.); Stanford Cancer Institute, Stanford, CA (S.S.); University of Washington and Fred Hutchinson Cancer Research Center, Seattle (S.S.T.); Vanderbilt University Medical Center, Nashville (J.A.S.); Fondazione Istituto Nazionale Tumori, Milan (G.P.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Hospital Universitario 12 De Octubre, Madrid (D.C.); Westmead Hospital and Macquarie University, Sydney (H.G.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Helsinki University Central Hospital and University of Helsinki, Helsinki (P.B.); South West Wales Cancer Institute and Swansea University College of Medicine, Swansea (J.W.), and Royal Marsden Hospital, London (J.L.) - both in the United Kingdom; University Hospital Essen of University of Duisburg-Essen, Germany (T.C.G.); Chiba Cancer Center, Chiba (T.U.), and Niigata University, Niigata (Y.T.) - both in Japan; Hospital Sao Jose, Beneficencia Portuguesa de São Paulo, São Paulo (F.A.S.); British Columbia Cancer Agency, Vancouver, BC, Canada (C.K.); Bristol-Myers Squibb, Lawrenceville (J.S.S., I.M.W.) and Hopewell (L.-A.X.) - both in New Jersey; and M.D. Anderson Cancer Center, University of Texas, Houston (P.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510665DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719487PMC
November 2015

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.

Cell 2015 Sep;162(6):1271-85

Division of Dermatology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095-1662, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095-1662, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095-1662, USA; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095-1662, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2015.07.061DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821508PMC
September 2015

Therapeutic Advances and Treatment Options in Metastatic Melanoma.

JAMA Oncol 2015 Jun;1(3):380-6

Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee2Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.0565DOI Listing
June 2015